Navigation Links
Simple and Rapid Isolation of Plant RNA,,, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit

nt pellet to a fresh 50 ml tube without any carryover of the cell debris. If the pellet is loose, the supernatant should be filtered through an RNase-free Miracloth (Callbiochem).
  • Add 18 ml 70% ethanol to lysate and completely mix via very gentle, repeated inversion.
  • Add 4 ml well-mixed Perfect RNA Binding Matrix Solution and mix via gentle inversion.
  • Place two Perfect RNA Maxi Spin Columns into 50 ml centrifuge tubes and transfer lysate/Binding Matrix mixture to two Spin Column assemblies.
    Note: A modified preparation procedure for difficult tissues is described in the detailed protocol Step 6.
  • Centrifuge for 5 to 10 min. at 2,000 x g. Discard filtrate.
  • Add 10 ml Wash Solution I to each Spin Column and centrifuge for 5 min. at 2,000 x g. Carefully transfer Spin Columns to fresh centrifuge tubes without splashing Wash Solution I.
  • Add 10 ml Diluted Wash Solution II (ethanol not provided) to each Spin Column and centrifuge 5 min. at 2,000 x g. Carefully transfer dry Spin Columns to RNase-free 50 ml Collection Tubes (provided).
  • Add 1 ml Molecular Biology Grade Water to each Spin Column and vortex assemblies briefly.
  • Incubate at 50C for 5 min.
  • After incubation, vortex for 5 sec. and immediately centrifuge for 5 min. at 2,000 x g. Store recovered total RNA at 80C.
  • Results

    About 200 g RNA of each were obtained from 1 g source material of Arabidopsis leaves, flowers, or pods, while 5 g yielded about 800 g RNA, and 10 g yielded 850 g RNA. With respect to maize, the yields were somewhat lower: 180 g, 560 g, a
    '"/>

    Source:


    Page: All 1 2 3 4 5 6

    Related biology technology :

    1. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
    2. A Simple and Rapid Technique to Purify High-Quality Midiprep DNA
    3. Simple Purification of DNA from Plasmid Minipreps, PCR Amplifications and Agarose Gels
    4. Simple, Sensitive Isotyping of Mouse Monoclonal Antibodies
    5. Simple Isolation of RNA from Tissue and Cultured Cells
    6. HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex Virus DNA
    7. The Fastest, Simplest, and Most Effective Way to Remove DNA Contamination
    8. Simple Approaches for Optimization of RT-PCR
    9. Detection of Morphine and Morphine-Glucuronide in Saliva or Urine with a Rapid and Simple Method Without Derivatization on the Varian 500-MS
    10. Gram Quantities of MAb Produced with Simple Bioreactor in Serum-Free Perfusion Culture Replacing Ascitic Fluid Production
    11. CastAway Precast Gels for Rapid Automated DNA Sequence Analysis

    Post Your Comments:
    (Date:11/20/2009)...ecently announced that Dr. Dominique Hebrault will...s Analytical Technology (PAT) in Green Chemistry a..., (PRWEB) November 20, 200...chnology (PAT) in Green Chemistry and Green Engine...echnology (PAT) case studies will be presented on ...
    (Date:11/19/2009)...rstCall/ -- Omeros Corporation (Nasdaq: OMER ) to...third quarter ended September 30, 2009. For the th...ed a net loss of $3.9 million, or $1.34 per share,...54 per share, for the same period in 2008. For the... reported a net loss of $15.5 million, or $5.29 pe...
    (Date:11/19/2009)...irstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), ann... to its shareholders, discussing the Company,s acq...euticals Holdings, Inc. (CHBP), an integrated bio-...lic of China. The merger gives NeoStem a controlli...Ltd., CHBP,s primary operating subsidiary and a pr...
    (Date:11/19/2009)...er 19 MONITORING FORCE GmbH,announ...ibanserin in the,indication treatment-relevant lev...r orphan drug status designation with the European...sia is a complication of the mainstay,treatment in... of those,affected, since it may be disabling for ...
    Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
    ... 16 ,Boston Scientific Corporation (NYSE: BSX ) a...the signing of a definitive merger agreement, unde... price of $1.35 per share of,CryoCor, or approxima...elopment agreement, in place since June 2007, to p...n, or "Afib." Afib is the most common,cardiac arrh...
    ... Inc.,announced today that it has closed the secon...cing. As previously announced, Aisling Capital led...ew investors, the D.E. Shaw,group and Boston Life ...omura Phase4 Ventures, Novartis BioVentures, BioFu... Hentsch, BioVeda Fund and Hercules,Technology Gro...
    ... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ...er and his research group at St. James,s Universit...their work in the April 10 online issue of,Gene Th...Cell Killing by,Oncolytic Reovirus for the Treatme...eovirus effectively kills and replicates,in both h...
    Other Biology Technology:Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 6Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 2Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 3Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
    (Date:11/23/2009)..., Cambridge, Mass. November 23, 2009 Applied m...tain lily ( Hosta lancifolia ), a characteristic l...sely packed ripples along the edges. The simple ca... resulting from bending during differential growth... stretching foam ribbons. , Haiyi Liang, a postd...
    (Date:11/23/2009)... TORONTO, November 23, 2009 - The time of day mat...ng to a new paper produced by a research team led ...to Scarborough,s vice-principal for research and c...ology at the St. George campus. , Capitalizing...e poplar tree, the research team examined how popl...
    (Date:11/23/2009)... A new study by the Wildlife Conservation Society...rge swamp in the Republic of Congopart of the "mot... last yearare becoming increasingly threatened by ...dy recommends protection of the swamp forests adja...eserve after recent surveys confirmed that high de...
    Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Time of day matters to thirsty trees, U of T researcher discovers 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 1Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 3Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 4Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 5Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 6Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 7Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 8Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 9Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 10Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 11Celebrities Lead One Million Walkers and Urge Public to Support March for Babies 28R 29 48003 1Celebrities Lead One Million Walkers and Urge Public to Support March for Babies 28R 29 48003 2Celebrities Lead One Million Walkers and Urge Public to Support March for Babies 28R 29 48003 3Obesity May Dampen Response to Asthma Meds 48001 1Obesity May Dampen Response to Asthma Meds 48001 2
    ... expanding into new territory, successfully aiding...valves in patients too sick to withstand open-ches...th Annual Scientific Sessions of the Society for C..., May 9?2, 2007, in Orlando, FL, patients who were...Valve, Irvine, CA) experienced improvements in bot...
    ...e use of tissue-engineered scaffolding made of car... naturally, to replace defective cartilage tissue....caffold which is implanted into the body, where ne...he study appears in the journal Artificial Organs....d mice as the study found these scaffolds to be a ...
    ...e-dose anticlotting medication just before percuta...d risk of heart attack and cardiac death by half, ...cientific Sessions of the Society for Cardiovascul...2007, in Orlando, FL. , Researchers found that gi...e stenting, rather than the standard 300-mg dose, ...
    Other Biology News:Percutaneous aortic valve replacement safe, successful in high-risk patients 2High-dose anticlotting drug cuts heart attack, death risk in half 2
    ...RS are multi-functional mixing devices. Stepping m... solid, heavy-duty durable shaker to provide a uni...ature. Regulated action scale for all modes. Micro...trol time, continuous time, action scale and speed...
    Finnigan LTQ FT from Thermo Scientific
    PDQuest 10-User Network License from Bio-Rad
    Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation
    Biology Products: